Eli Lilly Beats Teva Appeal on Generic Cancer Drug

Jan 12, 2017

Reuters

A U.S. appeals court ruled that Eli Lilly and Co. can block Teva Pharmaceutical Industries Ltd from selling a generic equivalent of its lung cancer drug Alimta.

The U.S. Court of Appeals for the Federal Circuit agreed with a lower court finding that Teva and other defendants would be liable for inducing infringement by doctors who prescribe generic versions of Alimta, according to a Reuters article.

Teva spokeswoman Denise Bradley said the generic drugmaker is disappointed with the decision.

Read the Reuters story

Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.

Comments

No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments